An Open-label Phase I Dose Finding Study of BI 853520 Administered Orally in a Continuous Dosing Schedule in Japanese and Taiwanese Patients With Various Advanced or Metastatic Solid Tumours
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2014
At a glance
- Drugs BI 853520 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 21 Nov 2014 Interim results presented at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
- 06 Aug 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History